Izrael - héber - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 100 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Izrael - héber - Ministry of Health

trima israel pharmaceutical products maabarot ltd - lamotrigine - טבליה - lamotrigine 200 mg - lamotrigine - lamotrigine - epilepsy : monotherapy in adults and children over 12 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seiaures. primary generalised tonic clonic seizures. add- on therapy in adults and children over 2 years of age: simple partial seizures. complex partial seizures. secondarily generalised tonic clonic seizures. primary generalised tonic clonic seizures. adults ( 18 years of age and over) : lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Izrael - héber - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Izrael - héber - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Izrael - héber - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Izrael - héber - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Izrael - héber - Ministry of Health

עינת מדיקל סוכנויות בע"מ - צוות טכני

Izrael - héber - Ministry of Health

טרדיס גת בע"מ - רופא

Izrael - héber - Ministry of Health

gsk consumer healthcare, israel ltd - chlorhexidine digluconate - תמיסה - chlorhexidine digluconate 0.2 %w/v - chlorhexidine - chlorhexidine - antibacterial solution for the disinfection of the mouth.1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.

Izrael - héber - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.